Quantum Genomics Société Anonyme 将来の成長

Future 基準チェック /06

Quantum Genomics Société Anonymeの収益は年間171%で減少すると予測されていますが、年間利益は年間108.5%で増加すると予想されています。EPS は年間107.7%で増加すると予想されています。

主要情報

108.5%

収益成長率

107.7%

EPS成長率

Biotechs 収益成長	42.4%
収益成長率	-171.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	01 Dec 2023

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BST:2QG - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2024	N/A	-3	-3	-3	1
12/31/2023	N/A	-2	-2	-2	1
6/30/2023	0	-18	-17	-17	N/A
3/31/2023	1	-22	-18	-18	N/A
12/31/2022	3	-25	-20	-20	N/A
9/30/2022	3	-21	-22	-21	N/A
6/30/2022	5	-20	-23	-23	N/A
3/31/2022	5	-19	-20	-20	N/A
12/31/2021	6	-17	-17	-17	N/A
9/30/2021	7	-18	N/A	N/A	N/A
6/30/2021	8	-18	-12	-12	N/A
3/31/2021	6	-17	-12	-12	N/A
12/31/2020	4	-16	-12	-12	N/A
9/30/2020	4	-14	N/A	N/A	N/A
6/30/2020	0	-10	-10	-10	N/A
3/31/2020	0	-10	-10	-10	N/A
12/31/2019	2	-10	-11	-10	N/A
9/30/2019	0	-9	N/A	N/A	N/A
6/30/2019	0	-10	-12	-12	N/A
3/31/2019	0	-11	-11	-11	N/A
12/31/2018	0	-12	-11	-11	N/A
9/30/2018	N/A	-12	N/A	N/A	N/A
6/30/2018	0	-12	-10	-10	N/A
3/31/2018	0	-10	-9	-9	N/A
12/31/2017	N/A	-9	-8	-8	N/A
9/30/2017	N/A	-8	N/A	N/A	N/A
6/30/2017	N/A	-7	-6	-6	N/A
3/31/2017	N/A	-6	N/A	-6	N/A
12/31/2016	N/A	-5	N/A	-6	N/A
9/30/2016	0	-5	N/A	N/A	N/A
6/30/2016	0	-5	N/A	-5	N/A
3/31/2016	0	-4	N/A	-4	N/A
12/31/2015	0	-4	N/A	-3	N/A
9/30/2015	0	-3	N/A	N/A	N/A
6/30/2015	0	-3	N/A	-3	N/A
3/31/2015	0	-2	N/A	-3	N/A
12/31/2014	0	-2	N/A	-3	N/A
9/30/2014	0	-2	N/A	N/A	N/A
6/30/2014	0	-2	N/A	N/A	N/A
3/31/2014	0	-2	N/A	N/A	N/A
12/31/2013	0	-2	N/A	-1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 2QG今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 2QG今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 2QG今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 2QG来年は収益がないと予測されています。

高い収益成長: 2QG来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 2QGの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Quantum Genomics Société Anonyme 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2023

Forecast to breakeven in 2022

No longer forecast to breakeven

Recent updates

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

Less than half of directors are independent

Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, Fresh and Is Redirecting to New Developments

First half 2022 earnings released: €0.26 loss per share (vs €0.23 loss in 1H 2021)

Forecast breakeven date pushed back to 2023

Less than half of directors are independent

Quantum Genomics Announces the Appointment of Its New Scientific Advisory Board

No independent directors

Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH

Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606

Quantum Genomics Announces Granting of New Patents Protecting QGC606

No independent directors

No independent directors

Forecast to breakeven in 2022

No independent directors

Quantum Genomics Société Anonyme announced that it expects to receive $2 million in funding from Gulf Pharmaceutical Industries P.S.C.

No longer forecast to breakeven

No independent directors

No independent directors

No independent directors

Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat

Quantum Genomics Société Anonyme announced that it has received €0.87 million in funding from Orient EuroPharma Co., Ltd.

Quantum Genomics Launches Phase III Pivotal REFRESH Study in Difficult-to-treat/Resistant Hypertension with Once-a-day Formulation of Firibastat

New 90-day high: €5.37

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran

Quantum Genomics Signs Strategic Contract with Delpharm

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm

New 90-day high: €4.23

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Xediton Pharmaceuticals

New 90-day high: €3.62

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical to Develop and Commercialize Firibastat in Greater China Region, Hong Kong and Macao

Quantum Genomics Société Anonyme Announces Resignation of Jean-Paul Kress from the Board

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Orient EuroPharma (OEP)

New 90-day low: €2.10

New 90-day low - €2.25

New 90-day low - €2.39

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘